CN104873466A - Ceftriaxone sodium powder-injection for injection - Google Patents
Ceftriaxone sodium powder-injection for injection Download PDFInfo
- Publication number
- CN104873466A CN104873466A CN201510104263.1A CN201510104263A CN104873466A CN 104873466 A CN104873466 A CN 104873466A CN 201510104263 A CN201510104263 A CN 201510104263A CN 104873466 A CN104873466 A CN 104873466A
- Authority
- CN
- China
- Prior art keywords
- ceftriaxone
- inj
- acetone
- ceftriaxone sodium
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000479 ceftriaxone sodium Drugs 0.000 title claims abstract description 31
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 title claims abstract description 31
- 238000002347 injection Methods 0.000 title claims abstract description 9
- 239000007924 injection Substances 0.000 title claims abstract description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 56
- 238000001291 vacuum drying Methods 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000012065 filter cake Substances 0.000 claims abstract description 12
- 238000001914 filtration Methods 0.000 claims abstract description 11
- 230000001133 acceleration Effects 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 239000012046 mixed solvent Substances 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 238000005406 washing Methods 0.000 claims abstract description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 238000002425 crystallisation Methods 0.000 claims description 17
- 230000008025 crystallization Effects 0.000 claims description 17
- 229960004755 ceftriaxone Drugs 0.000 claims description 16
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- 239000012043 crude product Substances 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 abstract description 11
- 238000005516 engineering process Methods 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 10
- 230000008569 process Effects 0.000 abstract description 8
- 239000013078 crystal Substances 0.000 abstract description 7
- 239000002245 particle Substances 0.000 abstract description 5
- 239000012535 impurity Substances 0.000 abstract description 4
- 238000005457 optimization Methods 0.000 abstract description 3
- 230000007613 environmental effect Effects 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 238000000967 suction filtration Methods 0.000 abstract 1
- 238000005303 weighing Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YXIWHUQXZSMYRE-UHFFFAOYSA-N 1,3-benzothiazole-2-thiol Chemical compound C1=CC=C2SC(S)=NC2=C1 YXIWHUQXZSMYRE-UHFFFAOYSA-N 0.000 description 2
- -1 2-amino-4-thiazolyl Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KTAVBOYXMBQFGR-MAODNAKNSA-J tetrasodium;(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-1-oxidoethylidene]amino]-3-[(2-methyl-5,6-dioxo-1h-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C KTAVBOYXMBQFGR-MAODNAKNSA-J 0.000 description 2
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940081561 rocephin Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a ceftriaxone sodium powder-injection for injection. the powder-injection is prepared by the following steps: (1) weighing a ceftriaxone sodium crude raw material at 20 DEG C, adding water, stirring and dissolving, adding active carbon, decolouring, filtering, and washing with mixed solvents; (2) by a particle process crystal product molecular assembly and shape-state optimization technology of North China Pharmaceutical Hebei Huamin Pharmaceutical Co., Ltd., adding a solventing-out agent acetone according to a stream acceleration table at 15 DEG C at the stirring speed of 300 r/min; (3) carrying out suction filtration, washing a filter cake with acetone, putting the filter cake into a vacuum drying oven and carrying out vacuum drying at 30-40 DEG C; and (4) sub-packaging preparations of different specifications, and controlling environmental temperature and humidity until temperature is 20-24 DEG C and humidity is less than 40% so as to obtain the ceftriaxone sodium for injection. In comparison with a traditional technology, ceftriaxone sodium prepared by the above preparation method has advantages of less impurity, high stability and the like.
Description
Technical field
The present invention relates to a kind of ceftriaxone for inj injectable powder, belong to medical art.
Background technology
Ceftriaxone sodium, also known as rocephin, is the semi-synthetic cephalosporin of the third generation that is novel, long-acting, wide spectrum, belongs to beta-lactam antibiotic, play bactericidal action by the synthesis of anti-bacteria cell wall.Have powerful antibacterial activity to most of gram positive bacteria and negative bacterium, antimicrobial spectrum comprises bacillus pyocyaneus, escherichia coli, pneumobacillus, hemophilus influenza, aerogenesis enterobacteria, Proteus, Diplococcus and S. aureus L-forms etc.Clinical be mainly used in sensitive organism infect meningitis, pneumonia, skin soft-tissue infection, peritonitis, urinary system infection, gonorrhea, liver and gall infect, surgical wound, septicemia and genital infection etc.
Ceftriaxone sodium molecular formula C
18h
16n
8na
2o
7s
33.5H
2o, molecular weight is 661.59, and structural formula is as follows:
Its chemical name is [6R [6 α; 7 β (Z)]]-3-[[(1; 2; 5; 6-tetrahydrochysene-2-methyl-5; 6-dioxo-1,2,4-triazine-3-base) sulfo-] methyl]-7-[[(2-amino-4-thiazolyl) (methoxyimino) acetyl group] is amino]-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid disodium salt three times of semihydrates.
1969, Roche company of Switzerland takes to cephalosporin structure and bioactive research, and synthesized ceftriaxone sodium at Late Cambrian in 1978, code name is Ro-13-9904.Japan also to start the basic research of ceftriaxone sodium in 1978, and in November, 1980 and in June, 1981 successively carried out the Ith, II clinical trial phase.Early 1980s, Sichuan Industrial Institute of Antibiotics and Dongbei Pharmaceutical General Factory take the lead in launching at home basic research and the trial-production of ceftriaxone sodium, go through several years tackling key problem, successfully achieve suitability for industrialized production in the early 1990s.
It is little that the industrial crystallization process of ceftriaxone sodium faces product particle mean size, the uneven first-class phenomenon of particle size distribution, and cause because granularity is less than normal coalescent be cause one of ceftriaxone sodium crystalline product key factor off quality.As can be seen here, in industrial crystallization process, the control of Granularity Distribution has very important practical significance.
NCPC Hebei Huamin Pharmaceutical Co., Ltd.'s systematic study ceftriaxone sodium product form feature, establishes crystal habit optimization method, uses coupling crystallization new technique to achieve molecular assembly assembling with regularly arranged.And the equipment that exploitation is advanced, the configuration of optimization device and inside dimension, to reach excellent hydrodynamic performance, ensure that product crystal form is perfect, even particle size distribution.Due to influencing each other of Coupling Crystallization Alternative parameter, and the maximization of coupling crystallizer, control giving the computer of flow process to bring obvious large time delay to affect, for above controlling difficulties, utilize BACH system, and develop Adaptive Fuzzy Control algorithm software, solve the impact that large time delay effect associates with multivariate, ensure the operational stability of coupling crystallization flow process; Fully realize automatization and operation accuracy, reduce personal error.Consider that the general character of cephalo-type process of producing product is for realizing resource-sharing, the equipment that fully realizes maximizes economization and produces, and reduces product cost, and the Flexible Production Technology of exploitation advanced person is also the key of this project.From raw material to final products, each link of whole process is all optimized, and uses advanced technology, equipment and control and management system, ensures that whole production process is reached advanced world standards.
The less stable of ceftriaxone sodium, all unstable to heat, meta-acid environment, meta-alkali environment, show that outward appearance is easy to change, content reduces, occurs the problems such as catabolite, the reason of appearance may be to be mingled with in partial impurities, crystal formation the reasons such as residual solvent in crystallization.
Address this problem and must research and develop the crucial production technology of novel coupling crystallization, to optimize the process parameters such as solvent burden ratio, temperature, time, pressure, pH value, crystallization is carried out under the suitable conditions, thus ensure the quality of product.
Summary of the invention
The object of the invention is to provide a kind of preparation method of ceftriaxone for inj injectable powder, adopt the crucial production technology of novel coupling crystallization, the ceftriaxone for inj powder body obtained is made to reach excellent hydrodynamic performance, crystal form is perfect, even particle size distribution, the larger raising of color level, clarity, purity and stability.
For achieving the above object, the invention provides a kind of ceftriaxone for inj injectable powder, prepared by following steps:
(1) at 20 DEG C, take crude product of ceftriaxone sodium raw material, add distilled water, stirring and dissolving, add active carbon, filter after decolouring, wash filtering residue, filter flask with the mixed solvent of acetone and water, filtrate enters in crystallization bottle.
(2) at 15 DEG C, mixing speed is under 300 turns/min, presses surface low rate of acceleration and adds dissolved agent acetone:
| Time (min) | Rate of addition (ml/min) |
| 0-10 | 0.2-0.3 |
| 10-30 | 0 |
| 30-60 | 0.6-0.8 |
| 60-90 | 0.9-1.1 |
| 90-130 | 1.1-1.3 |
| 130-210 | 3.0-3.2 |
| 210-250 | 3.6-3.8 |
| 250-270 | 0 |
(3) sucking filtration, uses washing with acetone filter cake, filter cake is put into vacuum drying oven, at 30-40 DEG C vacuum drying, weigh, aseptic subpackaged.
Preferably, in step (1), the compound concentration of crude product of ceftriaxone sodium is not more than 0.4g/ml.
Preferably, in step (1), the volume ratio of mixed solvent acetone and water is 1 ~ 5:1.
Preferably, in step (1), the volume ratio of mixed solvent acetone and water is 1 ~ 3:1.
Preferably, in step (2), press surface low rate of acceleration and add dissolved agent acetone:
| Time (min) | Rate of addition (ml/min) |
| 0-10 | 0.2-0.3 |
| 10-30 | 0 |
| 30-60 | 0.7-0.8 |
| 60-90 | 1-1.1 |
| 90-130 | 1.2-1.3 |
| 130-210 | 3.1-3.2 |
| 210-250 | 3.7-3.8 |
| 250-270 | 0 |
Preferably, in step (2), press surface low rate of acceleration and add dissolved agent acetone:
| Time (min) | Rate of addition (ml/min) |
| 0-10 | 0.25 |
| 10-30 | 0 |
| 30-60 | 0.8 |
| 60-90 | 1 |
| 90-130 | 1.25 |
| 130-210 | 3.15 |
| 210-250 | 3.75 |
| 250-270 | 0 |
Preferably, in step (3), vacuum drying oven temperature is 35 ~ 40 DEG C.
Compared with the ceftriaxone sodium that traditional handicraft is obtained, the ceftriaxone sodium impurity that the present invention obtains is few, the few thus stability advantages of higher of residual solvent in raw material.
Accompanying drawing explanation
Fig. 1 is the microscope figure of ceftriaxone sodium prepared by the embodiment of the present invention 1;
Detailed description of the invention
Embodiment 1
(1) at 20 DEG C, the crude product of ceftriaxone sodium raw material of precise 30g, add the distilled water of 50mL, open stirring, about 10-15 minute dissolves completely, then adds 3g active carbon, decolour 30 minutes, filter, wash filtering residue, filter flask 2 times with the mixed solvent that 60ml volume ratio is (acetone: water=3:1), filtrate enters in crystallization bottle.
(2) at 15 DEG C, mixing speed is under 300 turns/min, presses surface low rate of acceleration and adds dissolved agent acetone:
| Time (min) | Acetone speed (ml/min) |
| 0-10 | 0.21 |
| 10-30 | 0 |
| 30-60 | 0.8 |
| 60-90 | 1 |
| 90-130 | 1.1 |
| 130-210 | 3.1 |
| 210-250 | 3.6 |
| 250-270 | 0 |
(3) carry out sucking filtration after crystallization, with 20ml*3 washing with acetone filter cake, filter cake is put into vacuum drying oven, vacuum drying oven temperature, at 40 DEG C, vacuum drying, to be weighed, subpackage.
Embodiment 2
(1) at 20 DEG C, the crude product of ceftriaxone sodium raw material of precise 30g, add the distilled water of 50mL, open stirring, about 10-15 minute dissolves completely, then adds 3g active carbon, decolour 30 minutes, filter, wash carbon, filter flask 2 times with the mixed solvent that 60ml volume ratio is (acetone: water=2:1), filtrate enters in crystallization bottle.
(2) at 15 DEG C, mixing speed is under 300 turns/min, presses surface low rate of acceleration and adds dissolved agent acetone:
| Time (min) | Acetone speed (ml/min) |
| 0-10 | 0.25 |
| 10-30 | 0 |
| 30-60 | 0.8 |
| 60-90 | 1 |
| 90-130 | 1.25 |
| 130-210 | 3.15 |
| 210-250 | 3.75 |
| 250-270 | 0 |
(3) filtration washing is dry, carries out sucking filtration, with 20ml*3 washing with acetone filter cake, filter cake is put into vacuum drying oven after crystallization, and vacuum drying oven temperature, at 35 DEG C, vacuum drying, to be weighed, subpackage.
Embodiment 3
(1) at 20 DEG C, the crude product of ceftriaxone sodium raw material of precise 30g, add the distilled water of 50mL, open stirring, about 10-15 minute dissolves completely, then adds 3g active carbon, decolour 30 minutes, filter, wash filtering residue, filter flask 2 times with the mixed solvent that 60ml volume ratio is (acetone: water=2:1), filtrate enters in crystallization bottle.
(2) at 15 DEG C, mixing speed is under 300 turns/min, presses surface low rate of acceleration and adds dissolved agent acetone:
| Time (min) | Acetone speed (ml/min) |
| 0-10 | 0.3 |
| 10-30 | 0 |
| 30-60 | 0.7 |
| 60-90 | 1.1 |
| 90-130 | 1.25 |
| 130-210 | 3.1 |
| 210-250 | 3.8 |
| 250-270 | 0 |
(3) carry out sucking filtration after crystallization, with 20ml*3 washing with acetone filter cake, filter cake is put into vacuum drying oven, vacuum drying oven temperature, at 35 DEG C, vacuum drying, to be weighed, subpackage.
Embodiment 4:
According to the aseptic ceftriaxone sodium of above-mentioned example suitability for industrialized production, getting 0.05kg respectively cleans between the rear subpackage sending into B level of de-bag, under A level laminar flow, adopt screw filling machine to be divided in sterile vial by former medicine according to different packing specifications (0.25g/ bottle, 0.5g/ bottle, 1.0g/ bottle, 2.0g/ bottle), the humiture that controls environment is 20 ~ 24 DEG C, humidity is less than 40%, obtains ceftriaxone for inj powder injection formulation.
Compared with conventional art, the ceftriaxone sodium crystal kenel that this technology is produced is homogeneous, and have obvious granule under microscope, crystal form is thick, as shown in Figure 1.
Ceftriaxone sodium belongs to the higher product of anaphylaxis, and the ceftriaxone sodium that this technology is produced is greatly improved on sensitization source, wherein 2-mercaptobenzothiazole can control even not detect in very substandard, and domestic similar manufacturer can detect substantially;
Ceftriaxone sodium color level all can control at below 3#, and content can reach more than 93%, and be in a leading position level; Single contaminant can control below 0.2%, and in product, impurity number is few, generally only has 1 to 2.
The ceftriaxone sodium injection that above-described embodiment and traditional handicraft are produced is simulated to go on the market and packs, temperature 40 DEG C, place 6 months under relative humidity 75% condition, respectively at the 1st, 2,3, sampling in June, investigate the project such as appearance character, color level, content, related substance, and with 0 day results contrast.
Shown in result of the test sees the following form:
As can be seen from above-mentioned accelerated test result, adopt ceftriaxone for inj injectable powder of the present invention within 6 months, to investigate through accelerated test, there is not significant change in indices, traditional handicraft then there occurs significant change.Therefore the stability of ceftriaxone sodium that prepared by the present invention is higher than conventional art.
More than describe preferred embodiment of the present invention in detail.Should be appreciated that those of ordinary skill in the art just design according to the present invention can make many modifications and variations without the need to creative work.Therefore, all technical staff in the art, all should by the determined protection domain of claims under this invention's idea on the basis of existing technology by the available technical scheme of logical analysis, reasoning, or a limited experiment.
Claims (7)
1. a ceftriaxone for inj injectable powder, is characterized in that, described ceftriaxone for inj injectable powder is prepared by following steps:
(1) at 20 DEG C, take crude product of ceftriaxone sodium raw material, add distilled water, stirring and dissolving, add active carbon, filter after decolouring, wash filtering residue, filter flask with the mixed solvent of acetone and water, filtrate enters in crystallization bottle;
(2) at 15 DEG C, mixing speed is under 300 turns/min, presses surface low rate of acceleration and adds dissolved agent acetone:
(3) sucking filtration, uses washing with acetone filter cake, filter cake is put into vacuum drying oven, at 30-40 DEG C vacuum drying, weigh, aseptic subpackaged;
(4) carry out the preparation subpackage of different size, the humiture that controls environment is 20 ~ 24 DEG C, and humidity is less than 40%, obtains ceftriaxone for inj powder injection formulation.
2. ceftriaxone for inj injectable powder according to claim 1, is characterized in that, in described step (1), the compound concentration of described crude product of ceftriaxone sodium is not more than 0.4g/ml.
3. ceftriaxone for inj injectable powder according to claim 1, is characterized in that, in described step (1), the volume ratio of described mixed solvent acetone and water is 1 ~ 5:1.
4. ceftriaxone for inj injectable powder according to claim 1, is characterized in that, in described step (1), the volume ratio of described mixed solvent acetone and water is 1 ~ 3:1.
5. ceftriaxone for inj injectable powder according to claim 1, is characterized in that, in described step (2), presses surface low rate of acceleration and adds dissolved agent acetone:
6. ceftriaxone for inj injectable powder according to claim 1, is characterized in that, in described step (2), presses surface low rate of acceleration and adds dissolved agent acetone:
7. ceftriaxone for inj injectable powder according to claim 1, is characterized in that, in described step (3), described vacuum drying oven temperature is 35 ~ 40 DEG C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510104263.1A CN104873466B (en) | 2015-03-10 | 2015-03-10 | A kind of ceftriaxone sodium for injection powder-injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510104263.1A CN104873466B (en) | 2015-03-10 | 2015-03-10 | A kind of ceftriaxone sodium for injection powder-injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104873466A true CN104873466A (en) | 2015-09-02 |
| CN104873466B CN104873466B (en) | 2018-05-22 |
Family
ID=53941324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510104263.1A Active CN104873466B (en) | 2015-03-10 | 2015-03-10 | A kind of ceftriaxone sodium for injection powder-injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104873466B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104926834A (en) * | 2015-05-28 | 2015-09-23 | 浙江长典医药有限公司 | Ceftriaxone sodium compound entity for children and preparation for ceftriaxone sodium compound entity for children |
| CN105418641A (en) * | 2015-12-30 | 2016-03-23 | 中山市金城道勃法制药有限公司 | Original-quality ceftriaxone sodium and pharmaceutical preparation thereof |
| CN106432278A (en) * | 2016-09-23 | 2017-02-22 | 临沂草之美医药科技有限公司 | Crystalline compound of drug ceftriaxone sodium for treating surgical operation infections |
| CN106432275A (en) * | 2016-09-21 | 2017-02-22 | 临沂草之美医药科技有限公司 | Method for preparing crystalline ceftriaxone sodium compound as drug for treating surgical infection |
| CN106432279A (en) * | 2016-09-23 | 2017-02-22 | 临沂草之美医药科技有限公司 | Method for preparing medicine ceftriaxone sodium crystal compound for treating surgical infection |
| CN106432274A (en) * | 2016-09-21 | 2017-02-22 | 临沂草之美医药科技有限公司 | Crystalline compound of drug ceftriaxone sodium for treating surgical operation infections |
| CN106562971A (en) * | 2016-09-30 | 2017-04-19 | 华北制药河北华民药业有限责任公司 | Ceftriaxone sodium powder-needle preparation production method |
| CN109010280A (en) * | 2018-07-23 | 2018-12-18 | 华北制药河北华民药业有限责任公司 | A kind of preparation method of ceftriaxone sodium for injection powder injection formulation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050059821A1 (en) * | 2003-09-17 | 2005-03-17 | Debashish Datta | Method for manufacture of ceftriaxone sodium |
| CN104370941A (en) * | 2014-12-15 | 2015-02-25 | 四川制药制剂有限公司 | Injection ceftriaxone sodium preparation method |
-
2015
- 2015-03-10 CN CN201510104263.1A patent/CN104873466B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050059821A1 (en) * | 2003-09-17 | 2005-03-17 | Debashish Datta | Method for manufacture of ceftriaxone sodium |
| CN104370941A (en) * | 2014-12-15 | 2015-02-25 | 四川制药制剂有限公司 | Injection ceftriaxone sodium preparation method |
Non-Patent Citations (3)
| Title |
|---|
| 曹观贞，等: "丙酮在头孢曲松钠精制中的应用与研究", 《临床合理用药》 * |
| 潘杰: "头孢曲松钠结晶过程研究", 《中国优秀博硕士学位论文全文数据库（硕士）》 * |
| 田红玉，等: "头孢曲松钠结晶工艺研究", 《煤炭与化工》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104926834A (en) * | 2015-05-28 | 2015-09-23 | 浙江长典医药有限公司 | Ceftriaxone sodium compound entity for children and preparation for ceftriaxone sodium compound entity for children |
| CN105418641A (en) * | 2015-12-30 | 2016-03-23 | 中山市金城道勃法制药有限公司 | Original-quality ceftriaxone sodium and pharmaceutical preparation thereof |
| CN105418641B (en) * | 2015-12-30 | 2018-08-10 | 广东金城金素制药有限公司 | It is a kind of former to develop quality Ceftriaxone Sodium and its pharmaceutical preparation |
| CN106432275A (en) * | 2016-09-21 | 2017-02-22 | 临沂草之美医药科技有限公司 | Method for preparing crystalline ceftriaxone sodium compound as drug for treating surgical infection |
| CN106432274A (en) * | 2016-09-21 | 2017-02-22 | 临沂草之美医药科技有限公司 | Crystalline compound of drug ceftriaxone sodium for treating surgical operation infections |
| CN106432278A (en) * | 2016-09-23 | 2017-02-22 | 临沂草之美医药科技有限公司 | Crystalline compound of drug ceftriaxone sodium for treating surgical operation infections |
| CN106432279A (en) * | 2016-09-23 | 2017-02-22 | 临沂草之美医药科技有限公司 | Method for preparing medicine ceftriaxone sodium crystal compound for treating surgical infection |
| CN106562971A (en) * | 2016-09-30 | 2017-04-19 | 华北制药河北华民药业有限责任公司 | Ceftriaxone sodium powder-needle preparation production method |
| CN106562971B (en) * | 2016-09-30 | 2019-03-22 | 华北制药河北华民药业有限责任公司 | A kind of preparation method of ceftriaxone sodium powder-needle preparation |
| CN109010280A (en) * | 2018-07-23 | 2018-12-18 | 华北制药河北华民药业有限责任公司 | A kind of preparation method of ceftriaxone sodium for injection powder injection formulation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104873466B (en) | 2018-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104873466A (en) | Ceftriaxone sodium powder-injection for injection | |
| CN102010426B (en) | Method for preparing ceftizoxime sodium | |
| CN103539803B (en) | A kind of method preparing ceftriaxone sodium | |
| CN104771372B (en) | A kind of cefuroxime sodium for injection powder injection formulation | |
| CN104666249B (en) | A kind of ceftazidime for injection powder injection formulation | |
| CN103275101B (en) | Prepare the method for cefotaxime sodium crystal | |
| CN105061472A (en) | One-pot synthesis method of ceftriaxone sodium | |
| CN105541870A (en) | Preparation method of cefazolin sodium with previous research quality and medicine preparation of cefazolin sodium | |
| CN103102357B (en) | A kind of synthetic method of Cefuroxime sodium | |
| CN101229129A (en) | Ceftezole sodium powder injection and synthesizing method thereof | |
| CN105418641A (en) | Original-quality ceftriaxone sodium and pharmaceutical preparation thereof | |
| CN109553626B (en) | Refining method of ceftizoxime sodium | |
| CN106478668A (en) | A kind of preparation technology of cefuroxime acid crystal | |
| CN101906109B (en) | Method for preparing cefuroxime sodium | |
| CN103319503A (en) | Preparation method of cefdinir | |
| CN103073562B (en) | Method for refining cefamandole nafate, cefamandole nafate and application thereof | |
| CN104887621A (en) | Children pharmaceutical composition containing ceftriaxone sodium and low-sodium carrier | |
| CN105566352A (en) | New crystal form cefmenoxine hydrochloride compound prepared by adopting particle process crystal product molecular assembling and morphology optimizing technology and preparation | |
| CN104926834A (en) | Ceftriaxone sodium compound entity for children and preparation for ceftriaxone sodium compound entity for children | |
| CN102559829A (en) | Synthetic method of ceftriaxone sodium crude salt | |
| CN106317080A (en) | Ceftazidime compound prepared by adopting coupling crystallization technology and preparation thereof | |
| CN108440569B (en) | Preparation method of ceftriaxone sodium spherical crystal | |
| CN117088896A (en) | Refining method of ceftiofur hydrochloride | |
| CN109053768A (en) | A kind of preparation method of unformed cefditoren | |
| CN106749410B (en) | A kind of preparation method of Ceftaroline Fosamil in high yield |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |